Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy?

Radiotherapy and Oncology

Volumn 94, Issue 3, 2010, Pages 324-327

  Goldner, Gregor ^a   Dimopoulos, Johannes ^a   Pötter, Richard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvant radiotherapy; Biochemical recurrence; Prostate cancer; Prostatectomy; Roach formula

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77949293235     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.12.031     Document Type: Article

References (12)

1. Swanson G.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225-2229
2. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181 (2009) 956-962
3. Bolla M., van Poppel H., Collette L., et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
4. Roach III M. Equations for predicting the pathologic stage of men with localized prostate cancer using the preoperative prostate specific antigen (PSA) and Gleason score. J Urol 150 (1993) 1923-1924
5. Roach III M., DeSilvio M., Valicenti R., et al. Whole-pelvis, "mini-pelvis", or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66 (2006) 647-653
6. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
7. Pommier P., Chabaud S., Lagrange J.L., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25 (2007) 5366-5373
8. Roach III M. Predicting pathologic stage, nomograms, and clinical judgment: don't miss the forest for the trees!. Int J Radiat Oncol Biol Phys 73 (2009) 325-326
9. Roach III M. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials. J Clin Oncol 26 (2008) 3816-3817 author reply 3817-8
10. Nguyen P.L., and D'Amico A.V. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol 25 (2007) 5366-5373
11. Spiotto M.T., Hancock S.L., and King C.R. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69 (2007) 54-61
12. Nguyen P.L., Chen M.H., Hoffman K.E., Katz M.S., and D'Amico A.V. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys 74 (2009) 104-109